TapewireFind a company

person · Reporting owner

LENZ BRIAN

Disclosed activity across 1 company

Tapewire entity
93306
SEC CIK
0001283260

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
ADMA BIOLOGICS, INC.ADMA · Entity 4477EVP, CFOMarch 06, 2024March 08, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ADMA BIOLOGICS, INC.

Report date March 06, 2024 · Filed March 08, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect703,002 Last balance in matching sequence After 2024-03-07 transaction · row 2 Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rows

Row 1 · 2024-03-06 · Tax withholding · Disposed 16,677 · Balance 719,967

F1: Includes (i) 101,382 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 68,750 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2: (continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3: (continued from footnote 2) and (v) 395,371 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Row 2 · 2024-03-07 · Tax withholding · Disposed 16,965 · Balance 703,002

F1: Includes (i) 101,382 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 68,750 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2: (continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3: (continued from footnote 2) and (v) 395,371 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Includes (i) 101,382 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 68,750 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2: (continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3: (continued from footnote 2) and (v) 395,371 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 07, 2024 Filed Mar 8, 2024 21:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 16,965 $6.16 $104,504.40
Disclosure

SEC source: 0001140361-24-012446 · form4.xml · nonDerivative · entry 2

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 703,002

F1 · balance_after: Includes (i) 101,382 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 68,750 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) and (v) 395,371 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 06, 2024 Filed Mar 8, 2024 21:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 16,677 $6.12 $102,063.24
Disclosure

SEC source: 0001140361-24-012446 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 719,967

F1 · balance_after: Includes (i) 101,382 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 68,750 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) and (v) 395,371 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 29, 2024 Filed Mar 4, 2024 21:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 4,935 $5.36 $26,451.60
Disclosure

SEC source: 0001140361-24-011193 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 736,644

F1 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021, of which 13,750 unvested RSUs will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) and (v) 360,845 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
February 25, 2024 Filed Feb 27, 2024 21:03 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 8,257 $5.26 $43,431.82
Disclosure

SEC source: 0001140361-24-009843 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 741,579

F1 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 13,750 unvested RSUs granted on February 25, 2021, of which 13,750 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 355,780 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
December 31, 2023 Filed Jan 5, 2024 21:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 16,908 $4.52 $76,424.16
Disclosure

SEC source: 0001140361-24-001139 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 749,836

F1 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 123,749 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 347,307 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 30, 2023 Filed Oct 3, 2023 21:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 15,268 $3.58 $54,659.44
Disclosure

SEC source: 0001140361-23-046742 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 766,744

F1 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 154,687 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 333,277 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 16, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 178,184 $4.45 $793,399.90
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 9

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 782,013

F2 · price: Reflects the weighted average price of sales on August 16, 2023. The shares were sold in multiple transactions at prices ranging from $4.40 to $4.535, inclusive.

F3 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 185,625 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F4 · balance_after: (continued from footnote 3) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F5 · balance_after: (continued from footnote 4) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 317,608 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (Right to Buy) · Derivative 192,472 $3.66 Strike: $3.66 $704,447.52
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · derivative · entry 15

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 192,472 shares

Expires 2027-06-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F11 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (Right to Buy) · Derivative 150,000 $3.71 Strike: $3.71 $556,500.00
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · derivative · entry 14

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires 2028-02-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F10 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (Right to Buy) · Derivative 200,000 $3.22 Strike: $3.22 $644,000.00
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · derivative · entry 13

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires 2029-01-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F9 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (Right to Buy) · Derivative 85,416 $2.92 Strike: $2.92 $249,414.72
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · derivative · entry 12

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,584

Underlying: Common Stock · 85,416 shares

Expires 2030-02-28

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (Right to Buy) · Derivative 83,979 $2.35 Strike: $2.35 $197,350.65
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · derivative · entry 11

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,021

Underlying: Common Stock · 83,979 shares

Expires 2031-02-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionStock Option (Right to Buy) · Derivative 97,395 $1.67 Strike: $1.67 $162,649.65
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · derivative · entry 10

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,605

Underlying: Common Stock · 97,395 shares

Expires 2032-03-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 631,078 $4.61 $2,909,269.58
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 8

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 960,197

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 192,472 $3.66 $704,447.52
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 7

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,591,275

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 150,000 $3.71 $556,500.00
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 6

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,398,803

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 200,000 $3.22 $644,000.00
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 5

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,248,803

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 85,416 $2.92 $249,414.72
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 4

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,048,803

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 83,979 $2.35 $197,350.65
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 3

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 963,387

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Exercise / conversionCommon Stock 97,395 $1.67 $162,649.65
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 2

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 879,408

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
August 15, 2023 Filed Aug 17, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 SaleCommon Stock 211,578 $4.60 $972,729.86
Disclosure

SEC source: 0001140361-23-040321 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 782,013

F1 · price: Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.60 to $4.65, inclusive.

Read SEC document
June 30, 2023 Filed Jul 5, 2023 21:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 15,268 $3.69 $56,338.92
Disclosure

SEC source: 0001140361-23-033191 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 993,591

F1 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 185,625 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 529,186 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 31, 2023 Filed Apr 4, 2023 21:08 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 15,469 $3.31 $51,202.39
Disclosure

SEC source: 0001140361-23-016460 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,008,858

F1 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 216,563 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 513,515 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 07, 2023 Filed Mar 8, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 16,965 $3.40 $57,681.00
Disclosure

SEC source: 0001140361-23-010773 · form4.xml · nonDerivative · entry 5

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,024,327

F1 · balance_after: Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 247,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 498,047 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 270,345 $0.00 Strike: $3.35 $0.00
Disclosure

SEC source: 0001140361-23-010773 · form4.xml · derivative · entry 6

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,345

Underlying: Common Stock · 270,345 shares

Expires 2033-03-06

F4 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027.

Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 135,175 $0.00 $0.00
Disclosure

SEC source: 0001140361-23-010773 · form4.xml · nonDerivative · entry 4

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,041,292

Read SEC document
February 28, 2023 Filed Mar 8, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 5,000 $3.55 $17,750.00
Disclosure

SEC source: 0001140361-23-010773 · form4.xml · nonDerivative · entry 3

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 906,117

Read SEC document
February 25, 2023 Filed Mar 8, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 7,927 $3.42 $27,110.34
Disclosure

SEC source: 0001140361-23-010773 · form4.xml · nonDerivative · entry 2

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 911,117

Read SEC document
February 25, 2023 Filed Mar 8, 2023 21:30 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 1,559 $3.42 $5,331.78
Disclosure

SEC source: 0001140361-23-010773 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 919,044

Read SEC document
January 04, 2023 Filed Jan 6, 2023 21:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 114,222 $3.87 $442,039.14
Disclosure

SEC source: 0001140361-23-000872 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 920,603

F1 · balance_after: Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 247,500 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F2 · balance_after: (continued from footnote 1) (iii) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F3 · balance_after: (continued from footnote 2) (iv) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 468,396 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
December 09, 2022 Filed Dec 9, 2022 16:41 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 6,993 $2.86 $19,999.98
Disclosure

SEC source: 0001140361-22-045112 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,034,825

F1 · shares: Represents a purchase from the underwriters in the December 2022 public offering of the issuer.

F2 · balance_after: Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F3 · balance_after: (iii) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F4 · balance_after: (iv) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 335,118 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 30, 2022 Filed Oct 4, 2022 21:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 73,678 $2.43 $179,037.54
Disclosure

SEC source: 0001140361-22-036163 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,027,832

F1 · balance_after: Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's (continued)

F2 · balance_after: (continued from prior footnote) continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (iv) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 328,125 shares of common stock owned by the reporting person, which reflects previous purchases and prior net settlements upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
May 11, 2022 Filed May 13, 2022 21:03 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 51,965 $1.43 $74,309.95
Disclosure

SEC source: 0001140361-22-019216 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,101,510

F1 · balance_after: Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 180,225 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the

F2 · balance_after: (continued from footnote 1) Compensation Committee of the Board of Directors, which shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and

F3 · balance_after: (continued from footnote 2) 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 221,578 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 23, 2022 Filed Mar 25, 2022 17:16 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 Tax withholdingCommon Stock 37,178 $1.46 $54,279.88
Disclosure

SEC source: 0001140361-22-011251 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,153,475

F1 · balance_after: Includes (i) 137,500 RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 495,000 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iii) 315,090 unvested Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation

F2 · balance_after: (continued from footnote 1) of the Compensation Committee of the Board of Directors, of which (x) 134,865 of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (y) 180,225 of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (iv) 47,207 unvested RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and

F3 · balance_after: (continued from footnote 2) 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 20,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 138,678 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 17:58 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 275,000 $0.00 Strike: $1.67 $0.00
Disclosure

SEC source: 0001140361-22-008673 · form4.xml · derivative · entry 2

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2032-03-07

F6 · derivative.exercise_date: The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 17:58 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 137,500 $0.00 $0.00
Disclosure

SEC source: 0001140361-22-008673 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,190,653

F1 · shares: These shares represent restricted stock units ("RSUs") that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date.

F2 · balance_after: Includes (i) 137,500 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 495,000 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F3 · balance_after: (continue from footnote 2) (iii) 405,000 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date

F4 · balance_after: (continue from footnote 3) (iv) 47,207 RSUs granted on February 25, 2021, of which 41,250 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 5,957 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (v) 20,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and

F5 · balance_after: (continue from footnote 4) (vi) 85,946 shares of common stock owned by the reporting person, which reflects shares previously purchased in the open market and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
October 25, 2021 Filed Oct 26, 2021 07:00 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 30,000 $1.00 $30,000.00
Disclosure

SEC source: 0001140361-21-035380 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,065,501

F1 · shares: Represents a purchase from the underwriters in the October 2021 public offering of the issuer.

F2 · balance_after: Includes (i) 495,000 Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F3 · balance_after: (ii) 405,000 Milestone-Based RSUs granted on September 29, 2021, subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date;

F4 · balance_after: (iii) 63,936 RSUs granted on February 25, 2021, of which 55,000 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 8,936 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F5 · balance_after: (iv) 30,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 71,565 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 29, 2021 Filed Oct 1, 2021 21:31 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 405,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-21-033355 · form4.xml · nonDerivative · entry 2

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,035,501

F2 · shares: These shares represent RSUs that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to milestone-based vesting conditions (the "Milestone-Based RSUs") established by the Board of Directors, upon the recommendation of the Compensation Committee of the Board of Directors, of which (x) 22.2% of the Milestone-Based RSUs shall become vested upon the completion of a debt refinancing which adds non-dilutive capital to the Company's balance sheet before or during the calendar year ending December 31, 2022, (y) 33.3% of the Milestone-Based RSUs shall become vested upon the achievement of a 15% gross margin on BIVIGAM without intermediates by the end of the fourth quarter of 2022, and (z) 44.5% of the Milestone-Based RSUs shall become vested upon the achievement of $35 million in quarterly revenues in or before the fourth quarter of 2022.

F3 · balance_after: Includes (i) 495,000 Time-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and that will be settled into common stock upon vesting; (ii) 405,000 Milestone-Based RSUs granted on September 29, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (2) and that will be settled into common stock upon vesting; (iii) 63,936 RSUs granted on February 25, 2021, of which 55,000 RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 8,936 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting;

F4 · balance_after: (continued from footnote 3) (iv) 30,000 RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (v) 41,565 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

Read SEC document
September 29, 2021 Filed Oct 1, 2021 21:31 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 495,000 $0.00 $0.00
Disclosure

SEC source: 0001140361-21-033355 · form4.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 630,501

F1 · shares: These shares represent restricted stock units ("RSUs") that will be settled into common stock upon vesting. Subject to the reporting person's continued employment on the applicable vesting date, these RSUs are subject to time based vesting conditions (the "Time-Based RSUs"), of which (x) 50% of the Time Based RSUs shall vest on December 31, 2022 ("Initial Vesting Date") and (y) 50% of the Time-Based RSUs shall vest in eight (8) equal quarterly installments over a period of two years following the Initial Vesting Date, becoming fully vested on December 31, 2024.

Read SEC document
February 25, 2021 Filed Mar 1, 2021 21:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 139,000 $0.00 Strike: $2.35 $0.00
Disclosure

SEC source: 0001193805-21-000291 · e620326_4-lenz.xml · derivative · entry 2

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,000

Underlying: Common Stock · 139,000 shares

Expires 2031-02-25

F3 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025.

Read SEC document
February 25, 2021 Filed Mar 1, 2021 21:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 63,936 $0.00 $0.00
Disclosure

SEC source: 0001193805-21-000291 · e620326_4-lenz.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,078

F1 · shares: These shares represent restricted stock units ("RSUs"). Of these RSUs, 55,000 RSUs will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 8,936 RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date. The RSUs will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 63,936 RSUs granted on February 25, 2021 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; (ii) 40,000 RSUs granted on February 28, 2020, which vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (iii) 36,142 shares of common stock owned by the reporting person.

Read SEC document
August 11, 2020 Filed Aug 12, 2020 08:02 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 4,000 $2.97 $11,860.00
Disclosure

SEC source: 0001193805-20-001004 · e619855_4-lenz.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,142

F1 · balance_after: Includes 40,000 RSUs granted on February 28, 2020, which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 19:08 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 100,000 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001193805-20-000286 · e619420_4-lenz.xml · derivative · entry 2

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2030-02-28

F3 · derivative.exercise_date: The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.

Read SEC document
February 28, 2020 Filed Mar 3, 2020 19:08 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantCommon Stock 40,000 $0.00 $0.00
Disclosure

SEC source: 0001193805-20-000286 · e619420_4-lenz.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,142

F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting.

F2 · balance_after: Includes (i) 40,000 RSUs granted on February 28, 2020 and reported on this Form 4, subject to vesting as set forth in footnote (1) and will be settled into common stock upon vesting; and (ii) 32,142 shares of common stock owned by the reporting person.

Read SEC document
February 11, 2020 Filed Feb 11, 2020 10:13 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 7,142 $3.50 $24,997.00
Disclosure

SEC source: 0001193805-20-000129 · e619336_4-lenz.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,142

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
May 17, 2019 Filed May 21, 2019 07:12 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 5,000 $4.00 $20,000.00
Disclosure

SEC source: 0001193805-19-000521 · e618480_4-lenz.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
January 23, 2019 Filed Jan 25, 2019 21:31 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 200,000 $0.00 Strike: $3.22 $0.00
Disclosure

SEC source: 0001193805-19-000092 · e618166_4-lenz.xml · derivative · entry 1

LENZ BRIAN · CIK 0001283260 · EVP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2029-01-23

F1 · derivative.exercise_date: The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023.

Read SEC document
June 08, 2018 Filed Jun 11, 2018 07:08 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 5,000 $4.78 $23,900.00
Disclosure

SEC source: 0001193805-18-000818 · e618084_4-lenz.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document
February 09, 2018 Filed Feb 13, 2018 21:01 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 GrantEmployee Stock Option (right to buy) · Derivative 150,000 $0.00 Strike: $3.71 $0.00
Disclosure

SEC source: 0001193805-18-000189 · e617683_4-lenz.xml · derivative · entry 1

LENZ BRIAN · CIK 0001283260 · VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2028-02-09

F1 · derivative.exercise_date: The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022.

Read SEC document
November 09, 2017 Filed Nov 13, 2017 13:49 UTC ADMA BIOLOGICS, INC. ADMA · Entity 4477 PurchaseCommon Stock 6,500 $2.15 $13,975.00
Disclosure

SEC source: 0001193805-17-003453 · e617470_4-lenz.xml · nonDerivative · entry 1

LENZ BRIAN · CIK 0001283260 · VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

F1 · shares: Represents a purchase from the underwriters in the Issuer's public offering.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.